Typically, abnormal levels of peptide amyloid-beta Aβ (Aβ+) in the cerebrospinal fluid or assessed via positron emission tomography (PET), in clinically normal (CN) individuals, are taken as a sign of preclinical AD (Jack et al. 2018; Sperling et al. 2011). The gene discussed is APP; the disease is Alzheimer disease.